Alberto Pablo-Trinidad

Alberto Pablo-Trinidad

Auto-generated profile, based on publicly available information

Alberto Pablo-Trinidad

Leuko Labs, Inc Boston, MA United States

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2019 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
APAlberto Pablo‐Trinidad
Alberto Pablo‐Trinidad
IBIan Butterworth
Ian Butterworth
MLMaría J. Ledesma‐Carbayo
María J. Ledesma‐Carbayo
TVTom Vettenburg
Tom Vettenburg
ÁSÁlvaro Sánchez-Ferro
Álvaro Sánchez-Ferro
ABAurélien Bourquard
Aurélien Bourquard
Click on the article title to read more.

9 August 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
GLGanimete Lamaj
Ganimete Lamaj
APAlberto Pablo-Trinidad
Alberto Pablo-Trinidad
IBIan Butterworth
Ian Butterworth
NBNolan Bell
Nolan Bell
RBRyan Benasutti
Ryan Benasutti
JSJohn Mark Sloan
John Mark Sloan
Background: Patients with cancer undergoing cytotoxic chemotherapy face an elevated risk of developing serious infection as a consequence of their treatment, which lowers their white blood cell count and, more specifically, their absolute neutrophil count. This condition is known as neutropenia. Neutropenia accompanied by a fever is referred to as febrile neutropenia, a common side effect of chemotherapy with a high mortality rate. The timely detection of severe neutropenia (<500 absolute neutrophil count/μL) is critical in detecting and managing febrile neutropenia. Current methods rely on blood draws, which limit them to clinical settings and do not allow frequent or portable monitoring. In this study, we demonstrated the usability of PointCheck, a noninvasive device for neutropenia screening, in a simulated home environment without clinical supervision. PointCheck automatically performs microscopy through the skin of the finger to image the blood flowing through superficial microcapillaries and enables the remote monitoring of neutropenia status, without requiring venipuncture. Objective: This study aimed to evaluate the usability of PointCheck, a noninvasive optical technology for screening severe neutropenia, with the goal of identifying potential user interface, functionality, and design issues from the perspective of untrained users. Methods: We conducted a multicenter study using quantitative and qualitative approaches to evaluate the usability of PointCheck across 154 untrained participants. We used a mixed method approach to gather usability data through user testing observations, a short-answer qualitative questionnaire, and a standardized quantitative System Usability Scale (SUS) survey to assess perceived usability and satisfaction. Results: Of the 154 participants, we found that 108 (70.1%) scored above 80.8 on the SUS across all sites, with a mean SUS score of 86.1 across all sites. Furthermore, the SUS results indicated that, out of the 151 users who completed the SUS survey, 145 (96%) found that they learned how to use PointCheck very quickly, and 141 (93.4%) felt very confident when using the device. Conclusions: We have shown that PointCheck, a novel technology for noninvasive, home-based neutropenia detection, can be safely and effectively operated by first-time users. In a simulated home environment, these users found it easy to use, with a mean SUS score of 86.1, indicating an excellent perception of usability and placing this device within the top tenth percentile of systems evaluated for usability by the SUS. Trial Registration: ClinicalTrials.gov NCT04448314; https://clinicaltrials.gov/ct2/show/NCT04448314 (Hospital Universitario 12 de Octubre registration) and NCT04448301; https://clinicaltrials.gov/ct2/show/NCT04448301 (Boston Medical Center registration)

18 February 2022 in JMIR Preprints
Verified
Preprint
Open access
GLGanimete Lamaj
Ganimete Lamaj
APAlberto Pablo-Trinidad
Alberto Pablo-Trinidad
IBIan Butterworth
Ian Butterworth
NBNolan Bell
Nolan Bell
RBRyan Benasutti
Ryan Benasutti
JSJohn Mark Sloan
John Mark Sloan
BACKGROUND Cancer patients undergoing cytotoxic chemotherapy face an elevated risk of developing serious infection as a consequence of their treatment, which lowers their white blood cell (WBC) count and, more specifically, their absolute neutrophil count (ANC). This condition is known as neutropenia. Neutropenia accompanied by a fever is referred to as febrile neutropenia (FN), a common side effect of chemotherapy with a high mortality rate. Timely detection of severe neutropenia (ANC < 500/μL) is critical in detecting and managing FN. Current methods rely on blood draws, which limit them to clinical settings and do not allow frequent or portable monitoring. In this study, we demonstrate the usability of PointCheck™, a non-invasive device for neutropenia screening, in a simulated home environment without clinical supervision. PointCheck™ automatically performs microscopy through the skin of the finger to image the blood flowing through superficial microcapillaries, and enables remote monitoring of neutropenia status, without requiring venipuncture. OBJECTIVE This study aims to evaluate the usability of PointCheck™, a non-invasive optical technology for screening severe neutropenia, with the goal of identifying potential User Interface (UI), functionality, and design issues from the perspective of untrained users. METHODS We conducted a multi-center study using quantitative and qualitative approaches to evaluate the usability of PointCheck™ across N=154 untrained participants. We used a mixed-method approach to gather usability data through user testing observations, a short-answer qualitative questionnaire, and a standardized quantitative System Usability Scale (SUS) survey to assess user experience and satisfaction. RESULTS We found that N=108 (70.1%) of participants scored above 80.8 on the SUS across all sites, with a mean SUS score of 86.1 across all sites. Furthermore, the SUS results indicated that N=145 (96.0%) of users who completed the SUS survey found they learned how to use PointCheck™ very quickly, and N= 141 (93.0%) felt very confident using the device. CONCLUSIONS We have shown that PointCheck™, a novel technology for non-invasive, home-based neutropenia detection, can be safely and effectively operated by first-time users. In a simulated home environment, these users found it easy to use, with a mean SUS score of 86.1, indicating excellent perception of user experience and placing this device within the top 10th percentile of systems evaluated for usability by the SUS. CLINICALTRIAL ClinicalTrials.gov: H12O: NCT04448314 https://clinicaltrials.gov/ct2/show/NCT04448314 BMC: NCT04448301 https://clinicaltrials.gov/ct2/show/NCT04448301